- Home
- PFLT vs WVE Comparison
PFLT vs WVE Comparison
Compare PFLT & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFLT
- WVE
- Stock Information
- Founded
- PFLT 2010
- WVE 2012
- Country
- PFLT United States
- WVE Singapore
- Employees
- PFLT N/A
- WVE N/A
- Industry
- PFLT Finance: Consumer Services
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- PFLT Finance
- WVE Health Care
- Exchange
- PFLT Nasdaq
- WVE Nasdaq
- Market Cap
- PFLT 1.1B
- WVE 915.6M
- IPO Year
- PFLT N/A
- WVE 2015
- Fundamental
- Price
- PFLT $10.47
- WVE $8.10
- Analyst Decision
- PFLT Buy
- WVE Strong Buy
- Analyst Count
- PFLT 5
- WVE 15
- Target Price
- PFLT $11.05
- WVE $20.07
- AVG Volume (30 Days)
- PFLT 636.8K
- WVE 1.6M
- Earning Date
- PFLT 08-11-2025
- WVE 07-30-2025
- Dividend Yield
- PFLT 11.75%
- WVE N/A
- EPS Growth
- PFLT N/A
- WVE N/A
- EPS
- PFLT 0.86
- WVE N/A
- Revenue
- PFLT $232,975,000.00
- WVE $93,946,000.00
- Revenue This Year
- PFLT $45.12
- WVE N/A
- Revenue Next Year
- PFLT $9.18
- WVE $4.55
- P/E Ratio
- PFLT $12.15
- WVE N/A
- Revenue Growth
- PFLT 49.56
- WVE N/A
- 52 Week Low
- PFLT $8.82
- WVE $5.04
- 52 Week High
- PFLT $11.90
- WVE $16.74
- Technical
- Relative Strength Index (RSI)
- PFLT 45.44
- WVE 56.69
- Support Level
- PFLT $10.40
- WVE $7.75
- Resistance Level
- PFLT $10.66
- WVE $8.57
- Average True Range (ATR)
- PFLT 0.14
- WVE 0.56
- MACD
- PFLT -0.04
- WVE -0.01
- Stochastic Oscillator
- PFLT 13.54
- WVE 50.32
About PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generate revenue in the form of interest income on the debt securities and dividends.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.